Meet our leaders

Transforming the 503B sterile compounding industry

QuVa was established in 2015. Our leadership team has pharma-grade backgrounds with deep expertise in FDA, cGMP, and aseptic manufacturing. They are resolute in the goal of making the 503B compounding industry more safe, efficient and reliable. We saw there was a better way to do business, then we built it, with the right people, processes and facilities.

QuVa's History

2015
2016
2017
2018
2019
2020
2021
·
August
Sugar Land, TX facility acquired
Group 662
·
October
QuVa generates first sales from Sugar Land, TX, compounding products from commercially available sterile starting material with full results of endotoxin, sterility and potency for its 40 SKU portfolio QuVa begins development of additional products to expand portfolio
Group 680
·
November
Temple, TX facility acquired, adding 10,000 sq ft of capacity and the ability to produce drug shortage items from bulk API to sterile production processes
Group 662-1
·
December
100+ employees
Group 680
·
October
Bloomsbury, NJ facility acquired
Group 662-1
·
December
200 Employees
Sugar Land, TX facility capacity expanded to 45,000 sq ft
Group 680
·
January
QuVa directly serving 230 hospital customers
Group 662-1
·
July
In-house Quality Control lab opened at Bloomsbury, NJ facility
Group 662-1
·
August
QuVa’s Texas facilities keep supply lines open as Hurricane Harvey hits the Gulf Coast
Group 662-1
·
December
300+ Employees
Product development efforts result in a portfolio that reaches 280 SKUs
Group 680
·
January
Invested capital exceeds $150M QuVa directly serving 750 hospital customers
Group 662-1
·
February
Sugar Land, TX facility doubles its production output
Group 662-1
·
March
Bloomsbury, NJ facility produces its first commercial compounded sterile products, brining additional redundancy and capacity online at the 160,000 sq ft facilityAdditional 17,000 sq ft added to Sugar Land, TX campus, now totaling over 60,000 sq ft
Group 662-1
·
December
600 Employees
Group 680
·
January
QuVa directly serving 1,350 hospital customers
Group 662-1
·
September
Bloomsbury, NJ facility doubles its production output
Group 662-1
·
December
QuVa grows to 750 Employees
Partnership with Smiths Medical announced to expand CADD Cassettes availability
Group 680
·
January
Invested capital exceeds $200 millionAnnouncement that QuVa expands into CardioplegiaQuVa directly serving over 2,200 hospital customersQuVa expands production of essential products to support COVID-19 and critically ill patients
Group 662-1
·
March
QuVa joins diverse group of stakeholders in the Compounding Quality Coalition QuVa becomes first Platinum Partner with ASHP Foundation
Group 662-1
·
August
QuVa Celebrates its 5th Year in Operation!
Group 662-1
·
December
850 Employees
74,000 sq ft of additional manufacturing space added in Sugar Land, TX
Group 680
·
May
QuVa Pharma announces the completion of $275 million financing with Goldman Sachs and Owl Rock Capital Partners
Group 662-1